MedTrace Logo

Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A

NCT04024137 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2020-06-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the antiviral effect, as measured by the time to alleviation of influenza symptoms and viral titer in nasopharyngeal secretions in adults with acute uncomplicated influenza A following administration of ZSP1273.

Conditions

Interventions

DRUG

ZSP1273 200 mg

1 X 200-mg tablet taken orally

DRUG

Placebo

2 tablets taken orally

DRUG

ZSP1273-400 mg

2 X 200-mg tablet taken orally

DRUG

Placebo

1 tablet taken orally

DRUG

ZSP1273-600 mg

3 X 200-mg tablet taken orally

DRUG

Placebo

3 tablets taken orally

DRUG

Placebo

Subjects will receive matching placebo of ZSP1273

Sponsors & Collaborators

  • Guangdong Raynovent Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-07
Primary Completion
2020-05-18
Completion
2020-05-18

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04024137 on ClinicalTrials.gov